Table 1.
Patient and transplant characteristics
| TCE-X | TCE-FD | |||
|---|---|---|---|---|
| Nonpermissive (n = 1166) | Permissive (n =1564) | Nonpermissive (n = 1279) | Permissive (n = 1451) | |
| Recipient age, n (%), y | ||||
| <19 | 213 (18) | 305 (19) | 250 (19) | 268 (18) |
| 20-59 | 901 (77) | 1167 (75) | 970 (76) | 1098 (76) |
| 60+ | 52 (5) | 92 (6) | 59 (5) | 85 (6) |
| Median (range), y | 39 (<1 to 66) | 38 (<1 to 66) | 38 (<1 to 66) | 39 (<1 to 66) |
| Recipient sex, n (%) | ||||
| Male | 649 (56) | 869 (56) | 701 (55) | 817 (56) |
| Female | 517 (44) | 695 (44) | 578 (45) | 634 (44) |
| Recipient race, n (%) | ||||
| White | 1088 (93) | 1435 (92) | 1191 (93) | 1332 (92) |
| African American | 27 (2) | 48 (3) | 29 (2) | 46 (3) |
| Asian | 15 (1) | 23 (1) | 15 (1) | 23 (2) |
| Pacific Islander | 21 (2) | 31 (2) | 24 (2) | 28 (2) |
| Native American | 2 (<1) | 5 (<1) | 3 (<1) | 4 (<1) |
| No data | 13 (1) | 22 (1) | 17 (1) | 18 (1) |
| Karnofsky score prior to HCT, n (%) | ||||
| <90 | 290 (25) | 374 (24) | 318 (25) | 346 (24) |
| ≥90 | 758 (65) | 1043 (67) | 836 (65) | 965 (66) |
| No data | 118 (10) | 147 (9) | 125 (10) | 140 (10) |
| Disease at HCT, n (%) | ||||
| AML | 585 (50) | 731 (47) | 623 (49) | 693 (48) |
| ALL | 308 (26) | 417 (26) | 344 (27) | 381 (26) |
| CML | 166 (14) | 245 (16) | 193 (15) | 218 (15) |
| MDS | 107 (10) | 171 (11) | 119 (9) | 159 (11) |
| Disease status at HCT, n (%) | ||||
| Early | 519 (45) | 703 (45) | 582 (46) | 640 (44) |
| Intermediate | 349 (30) | 417 (27) | 374 (29) | 392 (27) |
| Advanced | 298 (25) | 444 (28) | 323 (25) | 419 (29) |
| Graft type, n (%) | ||||
| Bone marrow | 572 (49) | 753 (48) | 626 (49) | 699 (48) |
| Peripheral blood | 594 (51) | 811 (52) | 653 (51) | 752 (52) |
| Donor age, n (%), y | ||||
| 18-32 | 567 (49) | 741 (47) | 622 (49) | 686 (47) |
| 33+ | 576 (49) | 790 (51) | 632 (49) | 734 (51) |
| No data | 23 (2) | 33 (2) | 25 (2) | 31 (2) |
| Median age (range), y | 33 (18-56) | 33 (18-57) | 33 (18-57) | 34 (18-57) |
| Donor/recipient sex match, n (%) | ||||
| Male/male | 488 (42) | 601 (38) | 523 (41) | 566 (39) |
| Male/female | 327 (28) | 423 (27) | 361 (28) | 389 (27) |
| Female/male | 161 (14) | 268 (17) | 178 (14) | 251 (17) |
| Female/female | 190 (16) | 271 (17) | 217 (17) | 244 (17) |
| No data | 0 | 1 (<1) | 0 | 1 (<1) |
| Donor/recipient CMV match, n (%) | ||||
| −/− | 381 (33) | 504 (32) | 429 (34) | 456 (31) |
| −/+ | 388 (33) | 549 (35) | 426 (33) | 511 (35) |
| +/− | 145 (12) | 178 (12) | 159 (12) | 164 (11) |
| +/+ | 232 (20) | 311 (20) | 246 (19) | 297 (21) |
| No data | 20 (2) | 22 (1) | 19 (2) | 23 (2) |
| Donor/recipient ABO match, n (%) | ||||
| Matched | 450 (39) | 646 (41) | 509 (40) | 587 (40) |
| Mismatched | 641 (55) | 809 (51) | 689 (53) | 761 (52) |
| No data | 75 (6) | 109 (8) | 81 (7) | 103 (8) |
| Total body irradiation, n (%) | ||||
| No | 505 (43) | 652 (42) | 546 (43) | 611 (42) |
| Yes | 649 (56) | 893 (57) | 720 (56) | 822 (57) |
| No data | 12 (1) | 19 (1) | 13 (1) | 18 (1) |
| In vivo T-cell depletion (ATG or alemtuzumab), n (%) | ||||
| No | 845 (72) | 1169 (75) | 919 (72) | 1095 (75) |
| Yes | 321 (28) | 395 (25) | 360 (28) | 356 (25) |
| DQB1 matching, n (%) | ||||
| Mismatch | 83 (7) | 143 (9) | 99 (8) | 127 (9) |
| Match | 1075 (92) | 1402 (90) | 1170 (91) | 1307 (90) |
| No data | 8 (<1) | 19 (1) | 10 (<1) | 17 (1) |
| Year of HCT, n (%) | ||||
| 1999-2006 | 754 (65) | 988 (63) | 823 (64) | 919 (63) |
| 2007-2011 | 412 (35) | 576 (37) | 456 (36) | 532 (37) |
| Median follow-up of survivors (range), mo | 61 (3-151) | 62 (3-150) | 61 (3-151) | 62 (3-150) |
Only DPB1- mismatched pairs that could be classified as nonpermissive or permissive by the TCE-X and the TCE-FD model are shown. GVHD prophylaxis was based on methotrexate, with or without cyclosporine A or other, or mycophenolate mofetil, cyclosporine A, or FK506 alone or with other.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin.